Table of Contents Author Guidelines Submit a Manuscript
Journal of Lipids
Volume 2012 (2012), Article ID 601796, 5 pages
http://dx.doi.org/10.1155/2012/601796
Research Article

Paraoxonase-1 55 LL Genotype Is Associated with No ST-Elevation Myocardial Infarction and with High Levels of Myoglobin

1Advanced Technology Centre for Aging Research, Italian National Research Centre on Aging (INRCA), INRCA-IRCCS, 60121 Ancona, Italy
2Centre of Biostatistics, Italian National Research Centre on Aging (INRCA), 60121 Ancona, Italy
3Institute of Child Health, University College London, London, UK
4Department of Experimental Pathology, University of Bologna, Bologna, Italy
5Interdipartimental Centre “L. Galvani”, University of Bologna, Bologna, Italy
6Department of Cardiology (CCU), Italian National Research Centre on Aging (INRCA), 60121 Ancona, Italy

Received 30 November 2011; Accepted 19 January 2012

Academic Editor: Mira Rosenblat

Copyright © 2012 Francesca Marchegiani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

It is well known that serum paraoxonase (PON1) plays an important role in the protection of LDL from oxidation. PON1 55 polymorphism is currently investigated for its possible involvement in cardiovascular diseases. The objective of our study is to verify if PON1 55 polymorphism is associated with risk of acute coronary syndrome (ACS) and with biochemical myocardial ischemia markers, such as troponin I, creatine kinase (CK)-MB, myoglobin, and C-reactive protein. We analysed PON1 55 polymorphism in a total of 440 elderly patients who underwent an ACS episode: 98 patients affected by unstable angina (UA), 207 AMI (acute myocardial infarction) patients affected by STEMI (ST elevation), and 135 AMI patients affected by NSTEMI (no ST elevation). We found that individuals carrying PON1 55 LL genotype are significantly more represented among AMI patients affected by NSTEMI; moreover, the patients carrying LL genotype showed significantly higher levels of myoglobin in comparison to LM + MM carriers patients. Our study suggests that PON1 55 polymorphism could play a role in the pathogenesis of cardiac ischemic damage. In particular, the significant association between PON1 55 LL genotype and the occurrence of a NSTEMI may contribute to improve the stratification of the cardiovascular risk within a population.